Molybdenum Tungsten Complexes Application in Anticancer and Antineoplastic Drugs

Molybdenum is a trace element of life needed by organisms. Lack of molybdenum in the human body can lead to a series of diseases. Such as Keshan disease, kidney stones, Kashin-Beck disease, hypertension and diabetes. In particular, molybdenum deficiency can increase the incidence of cancer and cancer.

At present, the use of ammonium tetrathiomolybdate as a target for neovascularization has entered the second phase of clinical treatment, and achieved good anti-cancer and anti-cancer effect, prolonging the life of patients.

But ammonium tetrathiomolybdate is very unstable and sensitive to light, water and oxygen. Therefore, it is necessary to keep it in a dry, light-proof and oxygen-free environment, usually in inert argon. Within 8 weeks, ammonium tetrathiomolybdate in capsules retained only 90% of the efficacy. Therefore, it is imperative to seek new anti-cancer and anti-cancer drugs with high efficiency, low toxicity, superiority or specificity to current clinical drugs and certain stability.

Tungsten is the homologous element of molybdenum and the active center of tungsten oxotransferase. In many organisms, tungsten oxotransferase coexists with molybdenum oxotransferase and has similar biochemical functions. Therefore, molybdenum tungsten complexes can be used to prepare highly effective anticancer and antineoplastic drugs.

It has been proved by scientific researchers that molybdenum tungsten complex has good water-solubility and fat-solubility. In scientific experiments, 10 Kunming mice were selected as a group. Tumor cells were taken from the abdominal cavity of mice. After treatment, the cells were diluted to 5*106/ml. Under sterile conditions, the cells were inoculated under the axilla of the left forelimb of mice. After 24 hours of inoculation, the mice were given drugs in groups and intraperitoneally injected once a day. For 10 consecutive days. On the 12th day, the average weight of each group was calculated and the standard deviation was P. Cyclophosphamide was the positive control group. LuI 100 mg/kg, 50 mg/kg and positive control all inhibited the growth of mouse sarcoma S180. The inhibition rates were 68.7 (P < 0.01), 32.2 (P < 0.01), 64.5 (0.01), respectively. The results showed that the molybdenum tungsten complex exhibited excellent inhibitory effect on mouse sarcoma S180, and it is hopeful to be used as a clinical target drug in the future.

• < Prev
• Next >